17,261 trials
Diffuse Large Cell B-lymphoma
Primary: Percentage of Patients With an Overall Response to Study Drug — 24.3; 12.5 percentage of participants
Charcot-Marie-Tooth Disease · Hereditary Neuropathy With Liability to Pressure Palsies · Genetic Disorders
Primary: Safety and Tolerability of PXT3003 — 21; 21; 19; 19 Participants
Generalized Anxiety Disorder
Primary: Hamilton Anxiety Rating Scale (HAM-A) — 25.9; 23.8; 20.9; 19.4 units on a scale — p=.17
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response (>50% Reduction From Baseline) — 14 Participants
Acute Heart Failure
Primary: Global Ranking of Predefined Events — 145.5; 155.7 rank — p=0.3087
Cutaneous Leishmaniasis
Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants
Methamphetamine Dependence
Primary: Number of Subjects Showing Abstinence — 14; 20 Participants
COCAINE-RELATED DISORDERS
Primary: Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml) — 36.7; 32.4 ng/ml
Anaemia
Primary: Change From Baseline in Hemoglobin (Hgb) at Week 4 — -0.64; -0.24; 0.08; 0.42 grams (g)/deciliter (dL)
Neurofibromatosis Type 1
Primary: Time to Disease Progression Based on Volumetric MRI — 15.4 Months
Melanoma
Primary: Percentage of Participants With Detectable Talimogene Laherparepvec Deoxyribonucleic Acid (DNA) During the First Three Cycles — 98.3; 100.0; 97.5; 31.7 percentage of…
Sarcoma
Primary: Maximum Tolerated Dose — 15; 45 mg/m2
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 89.2 percentage of participants
Hepatorenal Syndrome
Primary: Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide — 36.0; 11.9; 15.7; 10.5 hours
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 12.7; 16.7 Percentage of participants — p=0.204